As an additional example, in NOTCH1-driven T cell ALL, clinical trials using γ-secretase inhibitors (GSI) have shown limited efficacy owing to the presence of a reversible subpopulation of GSI-tolerant cells characterized by BRD4-dependent transcriptional programs. The gene discussed is BRD4; the disease is acute lymphoblastic leukemia.